GH
BEAM icon

GAM Holding’s Beam Therapeutics BEAM Stock Holding History

GAM Holding’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,856
Closed -$221K – 256
2022
Q1 		$221K Hold
3,856
– – 0.01% 298
2021
Q4 		$307K Hold
3,856
– – 0.01% 315
2021
Q3 		$336K Hold
3,856
– – 0.02% 255
2021
Q2 		$496K Buy
+3,856
New +$307K 0.02% 252

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

GAM Holding's BEAM Position: Q2 2022 in Review

GAM Holding sold out of Beam Therapeutics (BEAM) in Q2 2022, closing a stake of 3,856 shares — an estimated $221K sold.

GAM Holding first reported a position in BEAM in Q2 2021 and held it in 4 quarters. The position peaked at $496K in Q2 2021. 205 funds tracked by Wall St. Rank hold BEAM as of Q2 2022.

  • GAM Holding reported no remaining Beam Therapeutics position as of Q2 2022 after selling out during the quarter.
  • GAM Holding sold 3,856 Beam Therapeutics shares in Q2 2022, an estimated $221K.
  • GAM Holding first reported a position in Beam Therapeutics in Q2 2021 and held it in 4 quarters.
  • GAM Holding's Beam Therapeutics position peaked at $496K in Q2 2021.
  • 205 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2022.

Based on GAM Holding's 13F filing for Q2 2022, filed 21 Jul 2022.